Search

Displaying results 6681 - 6690 of 8171 in total
  1. Drug

    ICX-RHY

    go.drugbank.com/drugs/DB05716
    Experimental

    ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.

  2. Drug

    16-Bromoepiandrosterone

    go.drugbank.com/drugs/DB05107
    Investigational

    16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide.

  3. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    [A193026] The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. … [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to

  4. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    Boldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.

  5. Drug

    Rexlemestrocel-L

    go.drugbank.com/drugs/DB17606
    Investigational

    Rexlemestrocel-L is an investigational human bone marrow-derived allogeneic mesenchymal precursor cell (MPC) product.

  6. Drug

    CX-2009

    go.drugbank.com/drugs/DB16090
    Investigational

    CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

  7. Drug

    Ralmitaront

    go.drugbank.com/drugs/DB19128
    Investigational

    Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or

  8. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

  9. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  10. Drug

    PF-08046040

    go.drugbank.com/drugs/DB17555
    Investigational

    SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70.